05Jul/18
Genetech’s New Drug Rituxan Approved for the Treatment of Serious Immune Diseases as a New Breakthrough during 60 Years
A few days ago, Genentech, a Roche Group member, announced that the US FDA approved Rituxan® (rituximab) for the treatment of moderate to severe pemphigus vulgaris (PV). It is worth mentioning thatRead More…